PMID- 18452596
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 8
DP  - 2008 May 1
TI  - Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and 
      preoperative serum VEGF level in gastric cancer.
PG  - 123
LID - 10.1186/1471-2407-8-123 [doi]
AB  - BACKGROUND: Hypoxia influences tumor growth by inducing angiogenesis and genetic 
      alterations. Hypoxia-inducible factor 1alpha (HIF-1alpha), p53, and vascular 
      endothelial growth factor (VEGF) are all important factors in the mechanisms 
      inherent to tumor progression. In this work, we have investigated the 
      clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and 
      preoperative serum VEGF (sVEGF) level in gastric cancer.We immunohistochemically 
      assessed the HIF-1alpha, p53, and VEGF expression patterns in 114 specimens of 
      gastric cancer. Additionally, we determined the levels of preoperative serum VEGF 
      (sVEGF). RESULTS: The positive rates of p53 and HIF-1alpha (diffuse, deep, 
      intravascular pattern) were 38.6% and 15.8%, respectively. The VEGF 
      overexpression rate was 57.9%. p53 and HIF-1alpha were correlated positively with 
      the depth of invasion (P = 0.015, P = 0.001, respectively). Preoperative sVEGF 
      and p53 levels were correlated significantly with lymph node involvement (P = 
      0.010, P = 0.040, respectively). VEGF overexpression was more frequently observed 
      in the old age group (> or = 60 years old) and the intestinal type (P = 0.013, P 
      = 0.014, respectively). However, correlations between preoperative sVEGF level 
      and tissue HIF-1alpha, VEGF, and p53 were not observed. The median follow-up 
      duration after operation was 24.5 months. HIF-1alpha was observed to be a poor 
      prognostic factor of disease recurrence or progression (P = 0.002). CONCLUSION: 
      p53, HIF-1alpha and preoperative sVEGF might be markers of depth of invasion or 
      lymph node involvement. HIF-1alpha expression was a poor prognostic factor of 
      disease recurrence or progression in patients with gastric cancers.
FAU - Oh, Sung Yong
AU  - Oh SY
AD  - Department of Internal Medicine, Dong-A University College of Medicine, Busan, 
      Republic of Korea. drosy@freechal.com
FAU - Kwon, Hyuk-Chan
AU  - Kwon HC
FAU - Kim, Sung-Hyun
AU  - Kim SH
FAU - Jang, Jin Seok
AU  - Jang JS
FAU - Kim, Min Chan
AU  - Kim MC
FAU - Kim, Kyeong Hee
AU  - Kim KH
FAU - Han, Jin-Yeong
AU  - Han JY
FAU - Kim, Chung Ock
AU  - Kim CO
FAU - Kim, Su-Jin
AU  - Kim SJ
FAU - Jeong, Jin-sook
AU  - Jeong JS
FAU - Kim, Hyo-Jin
AU  - Kim HJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080501
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adenocarcinoma/*blood/blood supply/pathology/surgery
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/biosynthesis/blood
MH  - Female
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*biosynthesis
MH  - Immunohistochemistry
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/blood/pathology
MH  - Prognosis
MH  - Stomach Neoplasms/*blood/blood supply/pathology/surgery
MH  - Tumor Suppressor Protein p53/*biosynthesis
MH  - Vascular Endothelial Growth Factor A/*biosynthesis/*blood
PMC - PMC2397429
EDAT- 2008/05/03 09:00
MHDA- 2009/03/04 09:00
PMCR- 2008/05/01
CRDT- 2008/05/03 09:00
PHST- 2008/01/11 00:00 [received]
PHST- 2008/05/01 00:00 [accepted]
PHST- 2008/05/03 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/05/03 09:00 [entrez]
PHST- 2008/05/01 00:00 [pmc-release]
AID - 1471-2407-8-123 [pii]
AID - 10.1186/1471-2407-8-123 [doi]
PST - epublish
SO  - BMC Cancer. 2008 May 1;8:123. doi: 10.1186/1471-2407-8-123.